Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries. Manufactured by US ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...